Publications [#191208] of Aimee K Zaas

Papers Published

1. CD Pfeiffer, G Garcia-Effron, AK Zaas, JR Perfect, DS Perlin, BD Alexander, Breakthrough invasive candidiasis in patients on micafungin., Journal of clinical microbiology, vol. 48 no. 7 (July, 2010), pp. 2373-80, ISSN 1098-660X [doi]
   (last updated on 2011/05/02)

   Abstract:
   For Candida species, a bimodal wild-type MIC distribution for echinocandins exists, but resistance to echinocandins is rare. We characterized isolates from patients with invasive candidiasis (IC) breaking through >or=3 doses of micafungin therapy during the first 28 months of its use at our center: MICs were determined and hot-spot regions within FKS genes were sequenced. Eleven of 12 breakthrough IC cases identified were in transplant recipients. The median duration of micafungin exposure prior to breakthrough was 33 days (range, 5 to 165). Seventeen breakthrough isolates were recovered: FKS hot-spot mutations were found in 5 C. glabrata and 2 C. tropicalis isolates; of these, 5 (including all C. glabrata isolates) had micafungin MICs of >2 microg/ml, but all demonstrated caspofungin MICs of >2 microg/ml. Five C. parapsilosis isolates had wild-type FKS sequences and caspofungin MICs of 0.5 to 1 microg/ml, but 4/5 had micafungin MICs of >2 microg/ml. The remaining isolates retained echinocandin MICs of 2 microg/ml and clinical breakthrough or an alternative mechanism contributes to the nonsusceptible echinocandin MICs in C. parapsilosis requires further study.

   Keywords:
   Adolescent • Adult • Aged • Antifungal Agents • Candida • Candidiasis • Drug Resistance, Fungal • Echinocandins • Female • Fungal Proteins • Glucosyltransferases • Humans • Lipopeptides • Male • Microbial Sensitivity Tests • Middle Aged • administration & dosage • complications • drug effects* • genetics • genetics* • isolation & purification • microbiology* • pharmacology • therapeutic use*